24.1 C
New York

Tag: carriers

Flights to Eight Indian Cities Is Being Reinstated by Oman Air

With international flights incoming and outgoing from India having been suspended for over two years, the lifting of the embargo on March 27th comes as a great relief for airlines all over the globe to resume flights to India. Oman […]

Top News

Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting

Tag Template - News Hub PRO

CAMBRIDGE, Mass., and TOKYO, Mar 22, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually.

Four key symposium presentations explored how lecanemab's clinical efficacy data, overall amyloid-related imaging abnormality (ARIA) rates, biomarker relationships to clinical outcomes, potential dosing regimens, and administration have the potential to benefit people living with early AD.

1. Science of the Amyloid Cascade and Distinct Mechanism of Action (MoA) of Lecanemab

- BioArctic's Professor Lars Lannfelt presented the science of the amyloid cascade and studies evaluating lecanemab's distinct binding profile to antibodies created from patented sequences of two other clinical antibodies, aducanumab and gantenerumab. The three antibodies have different binding profiles to Abeta species. All three antibodies bind to fibrils, but with different selectivity. Lecanemab was the strongest Abeta binder and prefers protofibrils. Lecanemab's binding profile is critical to enriching our understanding of the features in clinical outcomes and safety. BioArctic has had a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of AD.

2. Key Trial Design Aspects and Clinical Outcomes of the Lecanemab Phase 2b (Study 201) Trial and Open-Label Extension (OLE) in Early AD

- Innovative Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study with OLE - Study 201 (published by Eisai in Alz Res Therapy 13;21) was prospectively designed as a blinded 18-month study. To accelerate the development program, Eisai used a Bayesian adaptive design with a prespecified 12-month Bayesian primary endpoint in addition to the prespecified traditional analysis at the end of the 18-month treatment period. The OLE evaluated the long-term safety and tolerability of lecanemab and the effect of lecanemab on amyloid PET over 12 months of treatment, which looked at treatment naive patients (those on placebo during the core study) and those patients who had previously been treated with lecanemab, including earlier time points (3 and 6 months) than in the core phase (12 and 18 months). Eisai's study design provided the opportunity to explore the biomarker and clinical effects of stopping and restarting lecanemab across five years of disease trajectory.

- Rapid and Thorough Amyloid Clearance Correlates with Clinical Benefit - By using the Bayesian study design across a broad range of doses, researchers were able to efficiently and effectively identify the most effective dose, 10 mg/kg biweekly, to produce rapid and thorough amyloid clearance and potential clinical efficacy. Of the approximately 12 treatment-naive patients in the OLE (those who received placebo in the Core study), more than 40 percent were amyloid negative as early as 3 months and more than 80% were amyloid negative by 12 months as measured by PET image (visual read).(1) The OLE results are consistent with core phase results in which 65% were amyloid negative at 12 months(1) and 81% of participants were amyloid negative at 18 months as measured by PET image (visual read) in 161 subjects treated with 10 mg/kg biweekly dose. Robust amyloid reduction in those receiving lecanemab in the Core study was maintained while off-treatment over the Gap period. Despite the small number of participants in the OLE, findings help confirm the results from the Core study: lecanemab rapidly and thoroughly cleared amyloid plaque from the brain. Study 201 established 10 mg/kg biweekly as the most effective dose of lecanemab based on ADCOMS. Lecanemab could potentially be administered at 10mg/kg on the first day of treatment and continue at biweekly intervals without titration.

ARIA Incidence, Frequency, Severity and Modeling
ARIA-E is an important adverse event of amyloid-lowering therapies that is critical to monitor and manage during treatment.

Study 201 Core ARIA-E Rates
ARIA-E was observed in allele groups administered 10 mg/kg biweekly at the following rates: overall ApoE4 carriers 14.3% (7/49), ApoE4 carriers homozygous 50.0% (5/10), ApoE4 carriers heterozygous 5.1% (2/39) and ApoE4 non-carriers 8.0% (9/112). The overall ARIA-E rate in the Core study was 9.9% (16/161) of patients treated with lecanemab 10 mg/kg biweekly compared with 0.8% (2/245) of placebo patients.

Study 201 OLE ARIA-E Rates
Although ApoE carriers were underrepresented in the 10 mg/kg biweekly group in Study 201 Core, all participants entering Study 201 OLE (69.4% of whom were ApoE4 carriers) were treated with 10 mg/kg biweekly, and ARIA rates were consistent with those in the Core study. Forty-five participants who received placebo in the Core study joined the OLE. ARIA-E was observed in allele groups newly treated with 10 mg/kg biweekly in the OLE at the following rates: overall ApoE4 carriers 12.9% (4/31), ApE4 carriers homozygous 25.0% (1/4), ApoE4 carriers heterozygous 11.1% (3/27) and ApoE4 negative 0.0% (0/14). In the OLE study, overall ARIA-E rates were as follows: ApoE4 carriers 10.4% (13/125), ApoE4 carriers homozygous 14.3% (4/28), ApoE4 carriers heterozygous 9.3% (9/97) and ApoE4 non-carriers 1.8% (1/55).

Study 201 Core and OLE Pooled ARIA-E Rates
In the Core and the OLE, ARIA-E was observed in allele groups administered 10 mg/kg biweekly at the following rates: ApoE4 carriers 13.8% (11/80), ApoE4 carriers homozygous 42.9% (6/14), ApoE4 carriers heterozygous 7.6% (5/66) and ApoE non-carriers 7.1% (9/126). The overall ARIA- E rate was 9.7% (20/206) of patients treated with lecanemab 10 mg/kg biweekly.

ARIA-E Rates Frequency and Severity
In the Core study and OLE, the majority of ARIA-E events occurred within the first 3 months of treatment (75% [12/16]) and resolved within 4 months of onset. For the majority of patients, the radiographic severity was mild or moderate; severe radiographic severity was reported in 1.2% (2/161) of patients. The majority of ARIA-E was asymptomatic; with symptomatic ARIA-E reported in 1.9% (3/161) of patients. Symptoms reported in association with ARIA-E included headache, visual disturbance, confusion, aphasia. There has been a single case of ARIA-E associated with seizure in the Core study and OLE to date.

Exposure-Response Model Predicted and Observed ARIA-E vs. Cmax for APOE 4
The PK/PD exposure-ARIA-E model was developed from the Core study utilizing data from all doses and demonstrated that ARIA-E is driven primarily by Cmax. The ApoE4 genotype is a significant covariate in the model. The PK/PD model predicted ARIA-E by Cmax at the 10 mg/kg biweekly dose in the Core study by allele group as follows: ApoE4 carriers homozygous 22.5%, ApoE4 carriers heterozygous 6.8% and ApoE4 non-carriers 5.4%. In addition to the modeling predicting ARIA-E by Cmax in the Core study, it confirmed the observed ARIA-E in the OLE. Given the small data set for ApoE4 homozygous patients, this will be evaluated in Eisai's Phase 3 Clarity AD clinical trial.

ARIA-H Rates
In the Core study, the incidence was higher in ApoE4 homozygous carriers than in ApoE4 heterozygous carriers and non-carriers. ARIA-H was observed in 6.2% (10/161) of patients treated with lecanemab 10 mg/kg biweekly compared with 4.9% (12/245) of placebo patients. The rate of ARIA-H was higher in ApoE4 carriers (12.2% [6/49] vs placebo 5.2% [9/174]), than in ApoE 4 non- carriers (3.6% [4/112] vs placebo 4.2% [3/71]). All patients with microhemorrhage or superficial siderosis were asymptomatic. There has been one report of symptomatic cerebral macrohemorrhage. These data are hypothesis-generating and will be further evaluated in Clarity AD.

3. Phase 2b (Study 201) Lecanemab Early AD Study Biomarker Results, Correlations with Clinical Outcomes and Potential Less-Frequent Maintenance Dosing

- Abeta42/40 and P-Tau181 are plasma biomarkers that signal sequential changes in AD progression. Lecanemab has an effect on these plasma biomarkers as amyloid plaque reduction is related to soluble amyloid and P-Tau. Lecanemab has a dose- and time-dependent reduction of amyloid plaques with a correlated increase in plasma Abeta42/40 and a decrease in plasma P-Tau181. Changes in plasma Abeta42/40 and P-Tau18 also correlate with change from baseline Clinical Dementia Rating scale Sum of Boxes (CDR-SB). In the Core study, a correlation in change from baseline in amyloid PET SUVR and plasma Abeta42/40 ratio and plasma P-tau181 was observed at 18 months, indicating that plasma biomarkers could potentially help with measuring clinical changes.

- When lecanemab treatment was discontinued at the end of the Core study, changes in the plasma Abeta42/40 (47%), P-Tau18 (24%), and amyloid PET SUVR (21%), gradually began to reverse, suggesting stopping therapy prematurely may potentially allow re-accumulation of pathology. Less frequent maintenance treatment to prevent re-accumulation may be possible based on data and modeling. Eisai will further explore maintenance dosing in the subcutaneous substudy of the Study 201 OLE, which will evaluate alternative dosing every 4 weeks or every 12 weeks.

- Increasing strong evidence highlights the role of amyloid plaques in triggering tau dysregulation and researchers optimize tau therapeutics by removing a key driver of tau dyshomeostasis (amyloid). For this reason, the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, selected lecanemab as the backbone anti-amyloid therapy for anti-tau combination for the ongoing component of the Tau NexGen clinical study, which continues enrollment efforts.

4. Update on Lecanemab Clinical Development, Including New Subcutaneous Formulation
Eisai's Dr. Michael Irizarry Senior VP of Clinical Research and Deputy Chief Clinical Officer presented updates on key lecanemab clinical trials.

- Clarity AD Phase 3: The innovative Bayesian design of lecanemab's robust dose-ranging Phase 2b study allowed Eisai to design the Phase 3 confirmatory Clarity AD clinical trial to verify lecanemab's clinical efficacy and safety in early AD. Enrollment is complete with 1,795 participants globally. Additionally, Eisai's recruitment strategy for the Clarity AD clinical trial ensured greater inclusion of ethnic and racial populations in the U.S., resulting in approximately 25% of the total U.S. enrollment including Hispanic (22.5%) and African American (4.5%) persons living with early AD, which mirrors the U.S. Medicare population. The readout will occur in Fall 2022.

- AHEAD3-45 Phase 3 Study in Preclinical AD: As of March 2022, there were over 2,900 people screened, resulting in 287 participants enrolled.

- Clarity AD Subcutaneous Substudy: Eisai is developing a subcutaneous formulation of lecanemab with the potential to be administered at home by the patient or caregiver via an auto-injector with a more rapid administration than the IV formulation (<15 second SC injection versus ~1h infusion). PK/PD modeling of Study 201 suggests that the average lecanemab concentration (Cave) predicts amyloid clearance while the maximal lecanemab concentration (Cmax) predicts ARIA-E rate. Since subcutaneous administration results in a blunted Cmax, the SC dose with comparable Cave to 10 mg/kg IV is hypothesized to have similar amyloid reduction with potentially reduced incidence of ARIA-E relative to IV but less than half the ARIA- E rate as IV. Eisai is evaluating the SC formulation in the Clarity AD OLE.

"The invited lecanemab presentations at AD/PD provide new and exciting insights into how the mechanism of action of late-stage anti-amyloid antibodies differ and how that may help simplify the patient journey by offering a less frequent dosing regimen while providing long-term benefit," said Lynn Kramer, M.D., Chief Clinical Officer, Neurology Business Group, Eisai. "Eisai aims to bring these potential innovations to people living with early AD and healthcare providers as quickly as possible as we work to fulfill our human health care mission."

Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway. Eisai expects to complete this rolling submission in the first quarter of our fiscal year 2022, which begins April 1, 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval.

(1) Swanson C.et all, November, 9-12, 2021, Clinical Trials On Alzheimer's Disease Annual Meeting, Lecanemab: An Assessment of the Clinical Effects, the Correlation of Plasma Abeta 42/40 Ratio With Changes in Brain Amyloid PET SUVr, and Safety from the Core and Open Label Extension of the Phase 2 Proof-of- Concept Study, BAN2401-G000-201, in Subjects With Early Alzheimer's Disease.

Contacts:

MEDIA CONTACT:
Eisai Co., Ltd.
Public Relations Department
+81-(0)3-3817-5120

Eisai Inc. (U.S.) Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com

INVESTOR CONTACT:
Eisai Co., Ltd.
Investor Relations Department
+81-(0)70-8688-9685

MEDIA CONTACT:
Biogen Inc. Ashleigh Koss
+ 1-908-205-2572
public.affairs@biogen.com

INVESTOR CONTACT:
Biogen Inc. Mike Hencke
+ 1-781-464-2442
IR@biogen.com

For more information, visit https://www.eisai.com/news/2022/pdf/enews202221pdf.pdf.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually.

As post-pandemic travel reopens, direct flights from N.L. to Europe still not on the itinerary

From CBC News 🔗 link to source story St. John’s Airport Authority and WestJet say flight network planning and local demand are major factors Jonny Hodder • CBC News • March 19, 2022 With pandemic restrictions lifting across much of Canada and in many…

PayPal’s 3 Moves Help with Humanitarian Efforts in Ukraine

PayPal is boosting its humanitarian efforts in Ukraine. The payments company is expanding upon its P2P money transfer services, waiving fees, and facilitating funds transfers to payments cards. These efforts are being made in addition to the company’s Cash Pick-Up and Mobile Phone Reload tools. Citizens across the globe have donated millions of dollars in Read more...

The post PayPal’s 3 Moves Help with Humanitarian Efforts in Ukraine appeared first on Finovate.

Policygenius Raises Another $125M for its End-to-End Online Insurance Marketplace

The pandemic served as a driver for digital transformation across a number of industries.  Within the insurance sector, evolving customer expectations has insurance players rushing to adopt digital solutions to streamline the customer journey.  Policygenius has emerged as the leading online insurance marketplace where consumers can discover, compare, and purchase insurance.  The platform covers life, home, auto, disability, and rental insurance options across the largest and most trusted carriers, providing an experience similar to Kayak for travel. However, purchasing insurance is a bit more complicated than booking a plane ticket and Policygenius offers access to 400+ experts to navigate the entire process. For carriers, the company’s proprietary technology provides the conduit to access the digital insurance ecosystem through a proven and battle-tested online sales and marketing channel; the company has facilitated $90B in life insurance policies sold since 2014 for 30M+ individuals. AlleyWatch caught up with Policygenius CEO and Cofounder Jennifer Fitzgerald to learn more about the inspiration for the business, the company's strategic plans, latest round of funding, which brings the total funding raised to $276.1M, and much, much more...

Spirit Airlines Expands Las Vegas Operations Ahead of Frontier Merger

Spirit Airlines and Frontier Airlines are working towards merging the two ultra low-cost carriers (ULCC) through a proposed $6.6 billion alignment. And ahead of the fusion, the two airlines are expanding their Las Vegas operations. Just days after Frontier announced seven additional routes through Harry Reid International, Spirit is following suit with its own new […]

The post Spirit Airlines Expands Las Vegas Operations Ahead of Frontier Merger appeared first on Casino.org.

Mitsubishi Shipbuilding to Invest in Marindows

Tag Template - News Hub PRO

TOKYO, Mar 16, 2022 - (JCN Newswire) - Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has completed investment into Marindows Inc., a Tokyo-based firm aiming to utilize the revolution in information technology to build an integrated digital platform for the marine industry. Amid the current energy revolution, this partnership will accelerate efforts to achieve a carbon neutral world in areas from electrification and autonomous operation to the marine industry, create new value by merging the physical and digital, and establish a "win-win" relationship with substantial benefits for both companies.

Electrification and autonomous operation in the coastal vessel industry has become increasingly widespread, particularly in the small and mid-sized vessel market. This investment will provide a network with the small and mid-sized coastal vessel market, fishing boat market, and pleasure boat market that will support Mitsubishi Shipbuilding's efforts for the commercialization of standard electric propulsion vessels, and furthering the adoption of a safe and efficient navigation support system utilizing real-time data.

Marindows Inc. was established in March 2021 by e5 Lab Inc., a firm jointly founded by four companies representing shipping firms and a trading company to promote the electric propulsion and digitalization of ships. Marindows has adopted a vision to "Utilize the revolution in information technology to solve the issues of safety, productivity, and environmental conservation facing the marine industry, and transform the marine sector into one of the leading growth industries of the 21st century." The company aims to create a better work environment for crews and all personnel in the marine industry by providing a range of applications utilizing the "Marindows" marine operating system it provides as a platform. The launch of marine broadband in 2022 is expected to make possible ship to shore communications and crew support services in real time, which up to now had been unattainable because of the unreliability of such communications.

Mitsubishi Shipbuilding has built more than 5,000 vessels, including passenger ships, ferries, oceanographic research vessels and patrol boats, and has actively adopted new technologies as a pioneer in the construction of energy carriers including coal carriers, oil tankers, and liquified gas carriers (LPG and LNG carriers). In recent years, as a marine systems integrator generating innovation in the marine-related engineering and services business, Mitsubishi Shipbuilding has been pursuing initiatives that go beyond the conventional shipbuilding business model of just building and selling products. Through this investment, Mitsubishi Shipbuilding will continue to respond to the demands of customers and society, and work toward solutions to achieve its "MARINE FUTURE STREAM" growth strategy.

About MARINE FUTURE STREAM

Mitsubishi Shipbuilding has established the MARINE FUTURE STREAM vision for 2050 in the ship and marine sector, setting the goals of "effective utilization of the marine space" and "a decarbonized marine world," and working to generate ideas for marine-related innovation and achieving them through backcasting. For the effective utilization of the marine space, in order to stablish a safety society in which people work comfortably with the sea, and everyone is able to live well and with peace of mind, Mitsubishi Shipbuilding will utilize digital technologies and service businesses that extend beyond the confines of shipbuilding to establish a sound material-cycle society. For "a decarbonized marine world," in order to focus on the decarbonization of ships, as well as the use of renewable energy and CO2 capture at sea, Mitsubishi Shipbuilding will pursue the decarbonization of society through the marine business.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comMitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has completed investment into Marindows Inc., a Tokyo-based firm aiming to utilize the revolution in information technology to build an integrated digital platform for the marine industry.
Tag Template - News Hub PRO

Canada Jetlines builds to meet pent-up demand

From PAX International 🔗 link to source story By Jane Hobson • March 14, 2022 Canada Jetlines plans to take to the skies later this year Canada’s newest leisure airline plans to take to the skies this year with goals of…

Indian Airlines Ignoring Aerobridges for Boarding to Save Money

According to a Parliamentary committee, private airlines are preferring not to use aerobridges for boarding and deboarding planes in order to save money, and as a result, the elderly are feeling the brunt of having to use stairs. “The Committee […]

Government of Canada makes important investments at Thunder Bay International Airport

THUNDER BAY, ON, March 14, 2022 /CNW/ – As Canada works towards recovery from the COVID-19 pandemic, investments in our airports continue to be crucial to maintain safety, security, and connectivity for travellers, workers, and communities. Government of Canada investments also help ensure Canada’s airports are…

With a New Partnership, Copa Airlines Hopes to Spread Cost of Tickets

Uplift, a California-based buy-now-pay-later solutions company, has partnered with Copa Airlines, Panama’s flag carrier, to increase its reach in Central and South America. Passengers travelling with the airline may now stretch the cost of their ticket over several months, depending […]

How Ocean Shippers Are Coping With High Rates and Unreliable Service Contracts

With no immediate relief in sight from sky-high ocean container freight rates, shippers are faced with the question of how to negotiate with carriers for adequate capacity at a manageable price.

Air Canada to offer most number of flights between Canada and India

From Travelweek 🔗 link to source story By: Travelweek Group • March 11, 2022 MONTREAL — It’s easier than ever for Canadians to travel to India, thanks to Air Canada’s multiple flights to Delhi. By offering 21 return flights each week…
Tag Template - News Hub PRO

Recent articles

spot_img